Zydus Wellness PAT at Rs. 21.47 cr. in Q2FY22
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
Combination of hardware and data analytics software improves real-time and remote patient monitoring; digitizes and automates time-consuming and critical tasks for medical personnel, reducing administrative tasks by 35 per cent
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated